Lixte Biotechnology Holdings Inc (LIXTW) - Total Assets
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXTW) holds total assets worth $5.43 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lixte Biotechnology Holdings Inc (LIXTW) shareholders funds for net asset value and shareholders' equity analysis.
Lixte Biotechnology Holdings Inc - Total Assets Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's total assets have evolved over time, based on quarterly financial data.
Lixte Biotechnology Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lixte Biotechnology Holdings Inc's total assets of $5.43 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LIXTW market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lixte Biotechnology Holdings Inc's current assets represent 90.7% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 90.7% of total assets in 2024, down from 100.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lixte Biotechnology Holdings Inc Competitors by Total Assets
Key competitors of Lixte Biotechnology Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Lixte Biotechnology Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.42 | 5.13 | 24.15 |
| Quick Ratio | 10.42 | 5.13 | 24.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.91 Million | $1.36 Million | $5.01 Million |
Lixte Biotechnology Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Lixte Biotechnology Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -73.4% |
| Total Assets | $1.15 Million |
| Market Capitalization | $213.14 USD |
Valuation Analysis
Below Book Valuation: The market values Lixte Biotechnology Holdings Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lixte Biotechnology Holdings Inc's assets decreased by 73.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual total assets of Lixte Biotechnology Holdings Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Million | -73.41% |
| 2023-12-31 | $4.31 Million | -22.51% |
| 2022-12-31 | $5.56 Million | +9.16% |
| 2021-12-31 | $5.09 Million | -2.59% |
| 2020-12-31 | $5.23 Million | +95.67% |
| 2019-12-31 | $2.67 Million | -38.39% |
| 2018-12-31 | $4.34 Million | +217.00% |
| 2017-12-31 | $1.37 Million | +215.65% |
| 2016-12-31 | $433.41K | -27.52% |
| 2015-12-31 | $597.98K | +10.88% |
| 2014-12-31 | $539.30K | -3.36% |
| 2013-12-31 | $558.04K | -68.17% |
| 2012-12-31 | $1.75 Million | +307.90% |
| 2011-12-31 | $429.77K | -77.75% |
| 2010-12-31 | $1.93 Million | +20.61% |
| 2009-12-31 | $1.60 Million | +3000.20% |
| 2008-12-31 | $51.65K | -91.79% |
| 2007-12-31 | $629.11K | -16.24% |
| 2006-12-31 | $751.07K | +16118.25% |
| 2005-12-31 | $4.63K | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more